JP2012504590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504590A5 JP2012504590A5 JP2011529636A JP2011529636A JP2012504590A5 JP 2012504590 A5 JP2012504590 A5 JP 2012504590A5 JP 2011529636 A JP2011529636 A JP 2011529636A JP 2011529636 A JP2011529636 A JP 2011529636A JP 2012504590 A5 JP2012504590 A5 JP 2012504590A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- allergic
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010012434 Dermatitis allergic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000029771 childhood onset asthma Diseases 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0818033.3 | 2008-10-02 | ||
| GBGB0818033.3A GB0818033D0 (en) | 2008-10-02 | 2008-10-02 | Novel compound |
| PCT/GB2009/051303 WO2010038085A2 (en) | 2008-10-02 | 2009-10-02 | P38 mapk kinase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504590A JP2012504590A (ja) | 2012-02-23 |
| JP2012504590A5 true JP2012504590A5 (enExample) | 2013-05-16 |
| JP5571088B2 JP5571088B2 (ja) | 2014-08-13 |
Family
ID=40019929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529636A Active JP5571088B2 (ja) | 2008-10-02 | 2009-10-02 | ｐ３８ＭＡＰキナーゼ阻害剤 |
Country Status (32)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009077766A1 (en) | 2007-12-19 | 2009-06-25 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| WO2010067131A1 (en) * | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
| EP2236505A1 (de) * | 2009-04-03 | 2010-10-06 | Bayer CropScience AG | Acylierte Aminopyridine und - pyridazine als Insektizide |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB0921730D0 (en) * | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| JP5760010B2 (ja) | 2010-02-01 | 2015-08-05 | キャンサー・リサーチ・テクノロジー・リミテッド | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| EP2556068B1 (en) * | 2010-04-08 | 2019-01-23 | Respivert Limited | P38 map kinase inhibitors |
| WO2011124923A2 (en) | 2010-04-08 | 2011-10-13 | Respivert Limited | Novel compounds |
| GB201010193D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| GB201010196D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| US8933228B2 (en) | 2010-06-17 | 2015-01-13 | Respivert, Ltd. | Respiratory formulations and compounds for use therein |
| KR102057058B1 (ko) | 2011-10-03 | 2019-12-18 | 레스피버트 리미티드 | P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| RU2586333C1 (ru) * | 2011-12-09 | 2016-06-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные 4-гидрокси-1,2,3,4-тетрагидронафталин-1-ил-мочевины и их применение в лечении, среди прочего, заболеваний дыхательного тракта |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| TWI641592B (zh) | 2013-04-02 | 2018-11-21 | 英商瑞斯比維特有限公司 | 激酶抑制劑 |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| JP6514703B2 (ja) | 2013-12-20 | 2019-05-15 | トピバート ファーマ リミテッド | キナーゼインヒビターとして有用な尿素誘導体 |
| CN106164067B (zh) | 2014-02-14 | 2019-09-10 | 瑞斯比维特有限公司 | 作为抗炎化合物的芳族杂环化合物 |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| MA44607A (fr) | 2016-04-06 | 2021-05-19 | Oxular Acquisitions Ltd | Inhibiteurs de kinase |
| GB201611712D0 (en) | 2016-07-02 | 2016-08-17 | Hvivo Services Ltd | Methods and compounds for the treatment or prevention of severe or persistent influenza |
| GB201721793D0 (en) | 2017-12-22 | 2018-02-07 | Hvivo Services Ltd | Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza |
| EP3802525A4 (en) | 2018-05-30 | 2022-06-29 | Washington University | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof |
| KR102789258B1 (ko) * | 2022-10-26 | 2025-04-01 | (의료)길의료재단 | 신규화합물 및 이를 유효성분으로 포함하는 폐섬유화증 예방 또는 치료용 약학 조성물 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001521934A (ja) | 1997-11-03 | 2001-11-13 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症薬としての芳香族ヘテロ環式化合物 |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| AU762077B2 (en) | 1997-12-22 | 2003-06-19 | Bayer Healthcare Llc | Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas |
| AU739642B2 (en) | 1997-12-22 | 2001-10-18 | Bayer Healthcare Llc | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
| US20080300281A1 (en) | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
| EP1056725B1 (en) | 1997-12-22 | 2006-06-07 | Bayer Pharmaceuticals Corp. | Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas |
| EP1064289A1 (en) | 1998-03-18 | 2001-01-03 | Ariad Pharmaceuticals, Inc. | Heterocyclic signal transduction inhibitors, compositions containing them |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| EP1200411B1 (en) | 1999-07-09 | 2005-12-14 | Boehringer Ingelheim Pharmaceuticals Inc. | Process for synthesis of heteroaryl-substituted urea compounds |
| US6525046B1 (en) * | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| WO2002066442A1 (en) | 2001-02-15 | 2002-08-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents |
| JP2004530690A (ja) | 2001-05-16 | 2004-10-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症性薬剤として有用なジアリールウレア誘導体 |
| JP2004536845A (ja) | 2001-07-11 | 2004-12-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン媒介疾患の治療方法 |
| AU2003210969A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| US7041669B2 (en) * | 2002-02-25 | 2006-05-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-benzofused urea compounds useful in treating cytokine mediated diseases |
| IL163737A0 (en) | 2002-04-05 | 2005-12-18 | Boehringer Ingelheim Pharma | Method of treating mucus hypersecretion |
| US20040110755A1 (en) | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
| AU2003268424A1 (en) | 2002-09-05 | 2004-03-29 | Scios Inc. | Treatment of pain by inhibition of p38 map kinase |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| WO2004078746A2 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
| PL214032B1 (pl) | 2003-03-03 | 2013-06-28 | Array Biopharma | Zwiazki bedace inhibitorami kinazy p38, kompozycja farmaceutyczna je zawierajaca oraz ich zastosowanie do wytwarzania leku do leczenia stanu, w którym posredniczy kinaza p38 |
| GB0308511D0 (en) | 2003-04-14 | 2003-05-21 | Astex Technology Ltd | Pharmaceutical compounds |
| GB0320244D0 (en) | 2003-05-06 | 2003-10-01 | Aventis Pharma Inc | Pyrazoles as inhibitors of tumour necrosis factor |
| WO2004101529A1 (ja) | 2003-05-19 | 2004-11-25 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| BRPI0413757A (pt) | 2003-08-22 | 2006-10-31 | Boehringer Ingelheim Pharma | métodos para o tratamento de copd e da hipertensão pulmonar |
| EP1684762A4 (en) | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
| JP2007535558A (ja) | 2004-04-29 | 2007-12-06 | ファーミックス コーポレイション | キナーゼおよび／またはｈｍｇ−ｃｏａレダクターゼを阻害するための組成物および処置 |
| CN101010315A (zh) | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
| DE602005019874D1 (de) | 2004-05-12 | 2010-04-22 | Bristol Myers Squibb Co | Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1-rezeptors |
| WO2006009741A1 (en) | 2004-06-23 | 2006-01-26 | Eli Lilly And Company | Kinase inhibitors |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| US7612200B2 (en) | 2004-12-07 | 2009-11-03 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| EP1831228A1 (en) | 2004-12-20 | 2007-09-12 | AstraZeneca AB | Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors |
| EP2942349A1 (en) | 2004-12-23 | 2015-11-11 | Deciphera Pharmaceuticals, LLC | Enzyme modulators and treatments |
| AU2005325676A1 (en) | 2004-12-23 | 2006-08-03 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| GB0500435D0 (en) * | 2005-01-10 | 2005-02-16 | Novartis Ag | Organic compounds |
| DE102005015253A1 (de) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Pyrazolderivate |
| ES2352796T3 (es) | 2005-06-27 | 2011-02-23 | Bristol-Myers Squibb Company | Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas. |
| DE102005037499A1 (de) | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
| WO2007038425A2 (en) | 2005-09-27 | 2007-04-05 | Regents Of The University Of Minnesota | Anti-viral compouinds |
| EP1960394A2 (en) | 2005-11-15 | 2008-08-27 | Bayer HealthCare AG | Pyrazolyl urea derivatives useful in the treatment of cancer |
| US20110195110A1 (en) | 2005-12-01 | 2011-08-11 | Roger Smith | Urea compounds useful in the treatment of cancer |
| TW200817409A (en) | 2006-08-04 | 2008-04-16 | Takeda Pharmaceutical | Fused heterocyclic derivative and use thereof |
| WO2010014099A1 (en) * | 2008-07-31 | 2010-02-04 | Hewlett-Packard Development Company, L.P. | Nano-wire optical block devices for amplifying, modulating, and detecting optical signals |
| BRPI0920707A2 (pt) | 2008-10-02 | 2015-12-29 | Respivert Ltd | compostos |
| WO2010067131A1 (en) * | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
-
2008
- 2008-10-02 GB GBGB0818033.3A patent/GB0818033D0/en not_active Ceased
-
2009
- 2009-10-02 ES ES09736271T patent/ES2428917T3/es active Active
- 2009-10-02 UA UAA201103554A patent/UA104731C2/ru unknown
- 2009-10-02 RS RS20130407A patent/RS52979B/sr unknown
- 2009-10-02 CA CA2738827A patent/CA2738827C/en active Active
- 2009-10-02 KR KR1020117009956A patent/KR101660266B1/ko active Active
- 2009-10-02 MY MYPI20111436 patent/MY150611A/en unknown
- 2009-10-02 JP JP2011529636A patent/JP5571088B2/ja active Active
- 2009-10-02 HR HRP20130895AT patent/HRP20130895T1/hr unknown
- 2009-10-02 CN CN200980139617.9A patent/CN102203078B/zh active Active
- 2009-10-02 UA UAA201103555A patent/UA105014C2/uk unknown
- 2009-10-02 SI SI200930725T patent/SI2350047T1/sl unknown
- 2009-10-02 MX MX2011003552A patent/MX2011003552A/es active IP Right Grant
- 2009-10-02 AU AU2009299554A patent/AU2009299554B8/en active Active
- 2009-10-02 NZ NZ591426A patent/NZ591426A/xx unknown
- 2009-10-02 ME MEP-2013-108A patent/ME01604B/me unknown
- 2009-10-02 DK DK09736271.9T patent/DK2350047T3/da active
- 2009-10-02 PL PL09736271T patent/PL2350047T3/pl unknown
- 2009-10-02 WO PCT/GB2009/051303 patent/WO2010038085A2/en not_active Ceased
- 2009-10-02 PT PT97362719T patent/PT2350047E/pt unknown
- 2009-10-02 PE PE2011000798A patent/PE20110810A1/es not_active Application Discontinuation
- 2009-10-02 US US13/121,445 patent/US8293771B2/en active Active
- 2009-10-02 EA EA201170520A patent/EA019590B1/ru not_active IP Right Cessation
- 2009-10-02 EP EP09736271.9A patent/EP2350047B1/en active Active
-
2011
- 2011-03-25 CO CO11037006A patent/CO6351785A2/es active IP Right Grant
- 2011-04-01 EC EC2011010948A patent/ECSP11010948A/es unknown
- 2011-04-01 CL CL2011000735A patent/CL2011000735A1/es unknown
- 2011-04-01 HN HN2011000874A patent/HN2011000874A/es unknown
- 2011-04-01 NI NI201100062A patent/NI201100062A/es unknown
- 2011-04-29 ZA ZA2011/03181A patent/ZA201103181B/en unknown
- 2011-05-02 CR CR20110230A patent/CR20110230A/es unknown
-
2013
- 2013-09-05 SM SM201300097T patent/SMT201300097B/xx unknown
- 2013-09-25 CY CY20131100835T patent/CY1114665T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504590A5 (enExample) | ||
| NZ609147A (en) | Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors | |
| JP2016540749A5 (enExample) | ||
| ES2906227T3 (es) | Potenciador de efecto antitumoral | |
| JP2014528403A5 (enExample) | ||
| JP2016034968A5 (enExample) | ||
| JP2013523802A5 (enExample) | ||
| PH12014500103A1 (en) | Pyridin-2(1h)-one derivatives as jak inhibitors | |
| NZ545963A (en) | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | |
| CA2640672A1 (en) | 3 -deazapurine derivatives as tlr7 modulators | |
| MX2012007175A (es) | Derivados de imidazopiridina como inhibidores de jak. | |
| MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
| JP2015509973A5 (enExample) | ||
| JP2016529306A5 (enExample) | ||
| JP2010502767A5 (enExample) | ||
| TN2010000255A1 (en) | Organic compounds | |
| MX2008011369A (es) | Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2. | |
| RU2015111259A (ru) | Способы проведения терапии пирфенидоном | |
| MX2009009793A (es) | Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa. | |
| US20220119348A1 (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| JP2016503010A5 (enExample) | ||
| JP2020536893A5 (enExample) | ||
| JP2011530535A5 (enExample) | ||
| JP2018507223A5 (enExample) | ||
| JP2012509265A5 (enExample) |